CN105111303B - A kind of method that solid-liquid combination prepares Liraglutide - Google Patents
A kind of method that solid-liquid combination prepares Liraglutide Download PDFInfo
- Publication number
- CN105111303B CN105111303B CN201510347921.XA CN201510347921A CN105111303B CN 105111303 B CN105111303 B CN 105111303B CN 201510347921 A CN201510347921 A CN 201510347921A CN 105111303 B CN105111303 B CN 105111303B
- Authority
- CN
- China
- Prior art keywords
- fmoc
- liraglutide
- glu
- ala
- otbu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010019598 Liraglutide Proteins 0.000 title claims abstract description 54
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 title claims abstract description 53
- 229960002701 liraglutide Drugs 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 19
- 239000007788 liquid Substances 0.000 title claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 73
- 238000005583 trifluoroacetylation reaction Methods 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000000178 monomer Substances 0.000 claims abstract description 10
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000004048 modification Effects 0.000 claims abstract description 5
- 238000012986 modification Methods 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 60
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 57
- 238000006243 chemical reaction Methods 0.000 claims description 41
- 239000011347 resin Substances 0.000 claims description 41
- 229920005989 resin Polymers 0.000 claims description 41
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 23
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 23
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 22
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000003875 Wang resin Substances 0.000 claims description 12
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 12
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000005859 coupling reaction Methods 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims description 8
- 239000007790 solid phase Substances 0.000 claims description 8
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 150000003053 piperidines Chemical group 0.000 claims description 7
- 239000003513 alkali Substances 0.000 claims description 6
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical class COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000010612 desalination reaction Methods 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 claims description 5
- ZZGDWIAZPUAPHR-NSHDSACASA-N 1-o-tert-butyl 5-o-(2,5-dioxopyrrolidin-1-yl) (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OC(C)(C)C)CCC(=O)ON1C(=O)CCC1=O ZZGDWIAZPUAPHR-NSHDSACASA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 239000002516 radical scavenger Substances 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000007821 HATU Substances 0.000 claims description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 239000012317 TBTU Substances 0.000 claims description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 3
- 230000002101 lytic effect Effects 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 claims description 3
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 3
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 239000012670 alkaline solution Substances 0.000 claims description 2
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 claims description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 238000011017 operating method Methods 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 17
- 230000015572 biosynthetic process Effects 0.000 abstract description 15
- VXGGBPQPMISJCA-STQMWFEESA-N (2s)-2-[[(2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoyl]amino]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 VXGGBPQPMISJCA-STQMWFEESA-N 0.000 abstract description 7
- 239000012535 impurity Substances 0.000 abstract description 5
- 239000007791 liquid phase Substances 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 abstract description 2
- 238000007086 side reaction Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 23
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 8
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 6
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 5
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 4
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 4
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 4
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 125000001033 ether group Chemical group 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 3
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 2
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 2
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 2
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 2
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 2
- -1 2,2,4,6,7- pentamethyl benzofuran -5- sulfonyl Chemical group 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000012964 benzotriazole Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- CTYHQVFFQRDJSN-LHEWISCISA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[[(4-methoxyphenyl)-diphenylmethyl]amino]hexanoic acid Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)NCCCC[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 CTYHQVFFQRDJSN-LHEWISCISA-N 0.000 description 1
- YPTNAIDIXCOZAJ-LHEWISCISA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[[(4-methylphenyl)-diphenylmethyl]amino]hexanoic acid Chemical compound C1=CC(C)=CC=C1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)NCCCC[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 YPTNAIDIXCOZAJ-LHEWISCISA-N 0.000 description 1
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;n,n-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ZTRPYTHOEREHEN-UHFFFAOYSA-N piperazine pyridine Chemical compound N1CCNCC1.N1=CC=CC=C1.N1=CC=CC=C1 ZTRPYTHOEREHEN-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940118080 saxenda Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940007428 victoza Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to Peptides Synthesis, in particular to the method that a kind of chemical method combined using solid liquid phase prepares Liraglutide, the present invention can simplify the preparation process of Liraglutide, improve the quality standard of finished product;The present invention synthesizes two peptide monomer Fmoc-Lys (N- ε-(γ-Glu (N-Boc)-OtBu)-OH for the first time, and it is used for the preparation of Liraglutide, Liraglutide is prepared using Fmoc-Ala-Ala-OH participation simultaneously, avoid the generation of 24 or 25 missing Ala impurity peptides, purifying difficulty is reduced, yield is improved;The Liraglutide of trifluoroacetylation is (unmodified) water-soluble preferable, is conducive to Reverse phase chromatography and prepares, while also protecting the amino of N-terminal that side reaction does not occur in palmitinic acid modification, greatly improves the yield of finished product;Implementation of the invention solves the problems, such as that finished product related impurities peptide is exceeded during chemical synthesis Liraglutide, total recovery is low, obtains purity greater than 99.5%, single miscellaneous finished product less than 0.1% reduces production cost.
Description
Technical field
The present invention relates to polypeptide drugs preparation method field, in particular to a kind of solid phase and liquid phase combine and prepare Liraglutide
Method.
Background technique
Liraglutide (Liraglutide), trade name Victoza were researched and developed by danish novo nordisk, in 2010 1
The moon 25 listed in the U.S., SFDA approval was obtained on March 4th, 2011, into Chinese market;For adults with type 2 diabetes control
Blood glucose processed still controls bad trouble suitable for blood glucose after metformin alone or the treatment of sulfonylurea drugs maximum tolerable dose
Person, with melbine or sulfonylurea drugs use in conjunction.On December 23rd, 2014, Novo Nordisk Co., Ltd releases for treating fertilizer again
Fat Saxenda (trade name), dosage are 3mg/ days.
Liraglutide is a kind of GLP-1 analog, has 97% sequence homology with people GLP-1, and people GLP-1 can be tied
Merge activation GLP-1 receptor.GLP-1 receptor is the target spot of natural GLP-1, and GLP-1 is a kind of endogenous gut incretin hormones,
With can promoting pancreatic beta cell concentration of glucose dependence excreting insulin.Unlike natural GLP-1, Liraglutide exists
Pharmacokinetics and pharmacodynamic characteristics in human body are suitable for dosage regimen once a day.After subcutaneous administrations,
The mechanism of extended durations of action includes: to make to absorb the self association slowed down;In conjunction with albumin;To DPP IV (DPP-
IV) and neutral endopeptidase (NEP) has higher enzyme stability, to have longer plasma half-life.
Liraglutide chemistry is expressed as Arg34Lys26[N- ε-(γ-Glu (N- α-hexadecanoyl group))]-GLP-17-37, molecule
Formula is C172H265N43O51, relative molecular mass 3751.2, No. CAS is 204656-20-2, and sequence information is as follows:
Currently, Novo Nordisk Co., Ltd (US6458924 and US6268343) utilizes yeast mainly by gene recombination technology
Produce Liraglutide;But since main chain Arg can only be produced using gene recombination technology34-GLP-17-37, it is also necessary to and N- α-ten six
Acyl group-Glu (OSu)-OtBu reaction, using chemical method in Lys26Connect side chain;Due to Arg34-GLP-17-37Side chain not
Protection, there are multiple active sites, so this process can generate more impurity, lose larger.
It also has been reported that and Liraglutide is prepared using mechanochemical method, be concentrated mainly in the connection strategy of side chain modification: such as
Patent CN102286092A participates in peptide reaction, Pd (PPh) using Fmoc-Lys (Alloc)-OH3Alloc is taken off, then connecting side
Chain;CN103087181A participates in peptide reaction using Fmoc-Lys (Mtt)-OH or Fmoc-Lys (Mmt)-OH, uses 1%TFA/5%
TIS/DCM takes off Side chain protective group, connects side chain;CN103145828A participates in peptide reaction using Fmoc-Lys (ivDde)-OH,
Hydrazine hydrate takes off Side chain protective group, then connects side chain reaction;CN103980358A uses elder generation liquid phase synthesis monomer Fmoc-Lys (N- ε-
(γ-Glu (N- α-hexadecanoyl group)-OtBu)-OH, then participates in peptide reaction;CN103275209A is using first synthesis N-terminal protection
Liraglutide main chain use N then under liquid-phase conditionαCoupling reaction occurs therewith for-Pal- γ-Glu (OtBu)-OSu, so
Tert-butyl is taken off by sour TFA, Fmoc or the post-processing of two step of Dde (or ivDde) are taken off under alkaline condition, then purified obtains Li Lalu
Peptide.
The existing synthetic method of the present inventor prepares Liraglutide, it is found that purity and yield be not high, be unsuitable for industry
Large-scale production.In view of problem above, the present inventor studies the synthetic method of Liraglutide, to obtain of the invention
Technical solution.
Summary of the invention
In order to solve the deficiencies in the prior art, the present invention provides a kind of solid phase of Liraglutide and liquid phase combines preparation
Method.
In the present invention using synthesis two peptide monomer Fmoc-Lys (N- ε-(γ-Glu (N-Boc)-OtBu)-OH and
Fmoc-Ala-Ala-OH participation prepares Liraglutide, and using Liraglutide (unmodified) mode of trifluoroacetylation, greatly
Improve the yield of finished product;The present invention reduces synthesis difficulty and production cost, improves the purity and yield of fine peptide, is conducive to
Scale industrial production.A kind of skill book scheme that solid-liquid combination prepares Liraglutide method of the present invention includes the following steps:
(a) Boc-Glu (OSu)-OtBu and Fmoc-Lys-OH is coupled under alkaline solution generates two peptide monomer Fmoc-
Lys (N-ε-(γ-Glu(N-α-Boc)-OtBu)-OH;
(b) using Wang resin or CTC resin as solid phase carrier, using Fmoc chemoproection strategy, according to Liraglutide peptide
Sequence successively synthesizes the full guard peptide resin of N-terminal trifluoroacetylation, wherein Fmoc protected amino acid 26 with Fmoc protected amino acid
Using monomer Fmoc-Lys, (N- ε-(γ-Glu (N- α-Boc)-OtBu)-OH, 24 and 25 use two peptide monomers to Lys
Fmoc-Ala-Ala-OH;The full guard peptide resin structure of N-terminal trifluoroacetylation is as follows: Tfa-His (Trt)-Ala-Glu
(OtBu)-Gly-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Val-Ser(tBu)- Ser(tBu)-
Tyr(tBu)-Leu-Glu(OtBu)-Gly-Gln(Trt)-Ala-Ala-Lys(N-ε-(γ-Glu(N-α-Boc) -OtBu)-
Glu (OtBu)-Phe-Ile-Ala-Trp (Boc)-Leu-Val-Arg (Pbf)-Gly-Arg (Pbf)-Gly- resin;
(c) Liraglutide (unmodified) of trifluoroacetylation is obtained with lytic reagent peptide resin, and purified, obtained
Fine peptide: Tfa-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- Leu-Glu-Gly-Gln
-Ala- Ala -Lys(γ-Glu –OH)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg- Gly-OH;
(d) under alkaline condition, Liraglutide (unmodified) fine peptide of Pal- OSu and step (c) gained trifluoroacetylation
Coupling reaction occurs, obtains the product of palmitinic acid modification;
(e) Liraglutide is obtained through alkaline hydrolysis, purifying, freeze-drying.
Wherein Fmoc-Lys (the specific synthetic method of N- ε-(γ-Glu (N- α-Boc)-OtBu)-OH in above step (a)
Are as follows:
Fmoc-Lys-OH or its salt and alkali A are dissolved in water according to the ratio of molar ratio 1:1~2,5~20% bodies are added
Long-pending organic solvent B hydrotropy is added dropwise to 1~1.2 times of mole (with the amount of Fmoc-Lys-OH until completely dissolved, under stirring
Meter) Boc-Glu (OSu)-OtBu organic solvent B solution;TLC monitors reaction end, is evaporated under reduced pressure and removes to the end of reacting
After organic solvent, 10% aqueous citric acid solution tune solution ph is added to 2~3, ethyl acetate extraction, crystallization obtains Fmoc-Lys
(N-ε-(γ-Glu(N-α-Boc)-OtBu)-OH。
Alkali A is sodium carbonate, sodium bicarbonate, saleratus, potassium carbonate, triethylamine, diethylamine, N- ethyl two in above step
Isopropylamine, N, one of N- diisopropylethylamine etc.;
Organic solvent B be tetrahydrofuran, dioxane, N,N-dimethylformamide, acetone, n-methyl-2-pyrrolidone,
One or more of acetonitrile.
The full guard peptide resin of N-terminal trifluoroacetylation in above technical scheme step (b) specific the preparation method comprises the following steps: with
Wang resin or CTC resin are solid phase carrier, with 2-5 times of feed ratio (synthesize the substance meter of scale), are added corresponding
Fmoc protected amino acid carries out coupling reaction, and it is anti-that each coupling reaction is that the solid phase carried out in the presence of condensing agent connects peptide
It answers, removes Fmoc with deprotecting regent after completion of the reaction, then carry out coupling reaction with next Fmoc protected amino acid;It repeats to grasp
After making until being blended into 1 His, is blocked with trifluoroacetic anhydride, obtain the full guard peptide resin Tfa-His of N-terminal trifluoroacetylation
(Trt)- Ala-Glu(OtBu)-Gly -Thr(tBu)-Phe- Thr(tBu)-Ser(tBu)-Asp(OtBu)- Val-Ser
(tBu)-Ser(tBu)-Tyr(tBu)-Leu -Glu(OtBu)-Gly-Gln(Trt)-Ala-Ala- Lys(N-ε-(γ-Glu
(N-α-Boc)-OtBu) -Glu(OtBu)- Phe-Ile-Ala-Trp(Boc)-Leu-Val-Arg(Pbf)-Gly -Arg
(Pbf)-Gly- resin.The Fmoc protected amino acid that wherein 26 Lys are used is (the N- ε-of Fmoc-Lys made from step (a)
(γ-Glu (N- α-Boc)-OtBu)-OH, 24 and 25 Ala use Fmoc protected amino acid for two peptide monomer Fmoc-Ala-
Ala-OH;Other sites are all made of conventional Fmoc protected amino acid coupling.Preferably, Wang resin described in step (b)
Or the substitution degree of CTC resin is 0.3-0.5mmol/g;The condensing agent is DIC/HOBT, DIC/HOAT, TBTU/ HOBT/
One kind of DIPEA, HBTU/HOBT/DIPEA, HATU/HOAT/DIPEA;Deprotecting regent is 15~25%(volume content) piperazine
Pyridine/DMF solution.
Lytic reagent described in step (c) is the TFA solution that volume ratio 1-5% scavenger is added, institute in above-mentioned technical proposal
Stating scavenger is one of methyl phenyl ethers anisole, thioanisole, dithioglycol, mercaptoethanol, phenol, water and tri isopropyl silane or several
Kind.
The concrete operation step of step (d) in above-mentioned technical proposal are as follows:
Fine peptide obtained by step (c) and alkali A is taken to be dissolved in water according to the ratio of molar ratio 1:4~6, addition volume ratio 5~
20% organic solvent B hydrotropy is added dropwise to 1~2.0 times of mole (with the meter of fine peptide) Pal- until completely dissolved, under stirring
The organic solvent B solution of OSu;Continue to be stirred to react, TLC monitors reaction end;After reaction reaches terminal, it is added 1~2.0 times and rubs
The glycine (with the meter of fine peptide) of your amount terminates reaction.
Wherein alkali A described in step (d) is sodium carbonate, sodium bicarbonate, saleratus, potassium carbonate, triethylamine, diethyl
Amine, N- ethyl diisopropyl amine, N, one of N- diisopropylethylamine etc.;The organic solvent B is tetrahydrofuran, dioxy six
One or more of ring, N,N-dimethylformamide, acetone, n-methyl-2-pyrrolidone, acetonitrile.
In technical solution in step (e) alkaline hydrolysis concrete operation method are as follows: measure volume ratio 10-12% piperidines (with step
(d) resulting liquor capacity meter), it is added in step (d) resulting solution, is configured to the piperidine solution that concentration is 1M, stirring is anti-
It should be complete to trifluoroacetyl group alkaline hydrolysis;Then through ultrafiltration apparatus desalination, it is continuously added pure water dilution peptide solution, keeps liquor capacity
It is constant;When solution ph is down to 12~10, peptide solution is diluted using 0.2-1.0% aqueous acetic acid, until pH value is down to 5~6
When, stop filtering.
Compared with the existing technology, the beneficial effects of the present invention are:
The present invention synthesizes two peptide monomer Fmoc-Lys for the first time, and (N- ε-(γ-Glu (N-Boc)-OtBu)-OH, is used in combination
In the preparation of Liraglutide, synthesis process and purification process are simple and easy, detect convenient for middle control, are easy to amplify production;Simultaneously
Liraglutide is prepared using Fmoc-Ala-Ala-OH participation, the generation of 24 or 25 missing Ala impurity peptides is avoided, reduces
Purifying difficulty, improves yield;The Liraglutide of trifluoroacetylation is (unmodified) water-soluble preferable, and it is pure to be conducive to reverse-phase chromatography
Change preparation, while also protecting the amino of N-terminal that side reaction does not occur in palmitinic acid modification, greatly improves finished product
Yield;Implementation of the invention, solves during chemical synthesis Liraglutide that finished product related impurities peptide is exceeded, total recovery is low
Problem, the purity of finished product is increased to 99.5% or more, and single miscellaneous control is below 0.1%.
Specific embodiment
With specific embodiment, the present invention is described in detail below, but does not limit this patent;Change according to the present invention former
The feed ratio or reaction dissolvent of material or and condensing agent etc., be within the scope of the invention.
Abbreviation meaning used in specification and claims is as follows:
Fmoc | 9-fluorenylmethyloxycarbonyl |
CTC resin | 2- chlorine trityl chloride resin |
Wang Resins | Wang Shuzhi |
tBu | Tert-butyl |
Pbf | 2,2,4,6,7- pentamethyl benzofuran -5- sulfonyl |
Trt | Trityl |
Tfa | Trifluoroacetyl group |
Boc | Tertbutyloxycarbonyl |
EDPA | N- ethyl diisopropyl amine |
NMP | N-methyl-2-pyrrolidone |
DCM | Methylene chloride |
DMF | N,N-dimethylformamide |
DMAP | 4-dimethylaminopyridine |
DIPEA | N, N- diisopropylethylamine |
DIC | N, N- diisopropylcarbodiimide |
HBTU | Benzotriazole-N, N, N', N'- tetramethylurea hexafluorophosphate |
HATU | 2- (7- azo benzotriazole)-N, N, N', N'- tetramethylurea hexafluorophosphoric acid ester |
TBTU | O- benzotriazole-N, N, N', N'- tetramethylurea tetrafluoro boric acid |
HOBT | I-hydroxybenzotriazole |
HOAT | 1- hydroxyl -7- azo benzotriazole |
TFA | Trifluoroacetic acid |
TIS | Tri isopropyl silane |
Pal- OSu | Palmitinic acid active ester |
Embodiment 1:Fmoc-Lys (the synthesis of N- ε-(γ-Glu (N- α-Boc)-OtBu)-OH
It accurately weighs Fmoc-Lys-OH 183.8g (0.5mol) and sodium carbonate 63.6 (0.6mol) is dissolved in 1200mL water,
(2-8 DEG C) is slowly added to tetrahydrofuran solution (200.3g, 0.5mol)/1000ml of Boc-Glu (OSu)-OtBu under low temperature, stirs
Reaction is mixed, TLC monitors reaction end, after fully reacting, rotates THF, 10% aqueous citric acid solution tune solution is added under ice-water bath
PH value to 2~3,1000ml ethyl acetate extracts 3 times, merges organic phase, and 200ml saturated common salt is washed 3 times, and anhydrous sodium sulfate is dry
It is dry, concentrated by rotary evaporation to 1000ml, stand crystallization, obtain Fmoc-Lys (N- ε-(γ-Glu (N- α-Boc)-OtBu)-OH 253.6g,
Yield 73.5%.
The synthesis of embodiment 2:Fmoc-Gly-Wang Resins
Carrier Wang resin 400.0g (sub=0.47mmol/g) is placed in synthesis column, washs two with 2400mL DMF
It is secondary, 4000mL DCM is added and is swollen 30min;After leaching out DCM, the mixing DCM solution of Fmoc-Gly-OH/DIC/HOBT is added
It [weighs 118.8g (400mmol) Fmoc-Gly-OH and 64.8g (480mmol) HOBT and is placed in glycine activated bottle, be added
76.4ml (480mmol) is added under low temperature (0 DEG C) in DMF the and DCM mixed solution stirring and dissolving that 2000mL volume ratio is 1: 1
DIC is activated 5 minutes], 4.8g (4mmol) DMAP is added after reacting 10min;3h is reacted, reaction solution is taken out, with 4000mL DMF
It washes twice, capping reagent 2400mL (480ml acetic anhydride and 408ml pyridinium dissolution are in 1512mL DMF) is added and reacts 2h,
Reaction solution is leached out, is washed 2 times with DMF, DCM, methanol respectively, Fmoc-Gly-Wang Resins 436.6 is obtained after vacuum drying
G;It is 0.30mmol/g that substitution degree is surveyed in sampling.
The synthesis of embodiment 3:Fmoc-Gly-CTC Resins
It weighs CTC resin 50.0g (sub=0.40mmol/g) to be placed in synthesis column, is washed twice, added with 240mL DMF
Enter 240mL DCM swelling 30min;After leaching out DCM, the DCM/DMF dissolved with 5.94g (20mmol) Fmoc-Gly-OH is added
DIPEA 6.6ml (40mmol) is added after stirring in (3/1, volume ratio) solution 150ml, drum N260min is reacted, reaction solution is taken out,
DCM/CH is added3OH/DIPEA (volume ratio 17:2:1) mixed solution 300ml is blocked 3 times, each 10min;Then with DMF,
DCM, methanol wash 2 times respectively, are dried in vacuo to obtain Fmoc-Gly-CTC Resins 53.80g.Survey substitution degree is 0.29mmol/
g.
Embodiment 4: the preparation of peptide resin
Accurately weigh Fmoc-Gly-Wang Resins 100g (the synthesis rule that 2 substitution degree of embodiment is 0.30mmol/g
Mould 30mmol) it is placed in synthesis column, 1000ml DCM is added and is swollen 30min;After leaching out DCM, 800ml DMF is washed 2 times, is added
Enter 20% piperidines/DMF solution 1000ml to be deprotected 2 times, reacts 10min and 10min respectively;Then 800ml DMF, DCM, DMF are used
It washs 2 times respectively;Fmoc-Arg (Pbf)-OH 53.7g (90mmol), HOBT 13.4g (99mmol) and DIC 15.4ml is added
The DMF solution 500ml of (99mmol), drum N2It is stirred to react 2h, reaction end is subject to Kaiser reagent testing result, and reaction reaches
After terminal, reaction solution is taken out, is washed respectively 2 times with 800ml DMF, DCM, DMF;Then it is deprotected again.Circulation behaviour repeatedly
Make, according to Liraglutide peptide sequence, is coupled one by one with protected amino acid;Sequentially connected protected amino acid are as follows: Fmoc-Gly-OH,
Fmoc-Arg(Pbf)-OH、 Fmoc-Val-OH、Fmoc-Leu-OH、Fmoc-Trp(Boc)-OH、Fmoc-Ala-OH、Fmoc-
Ile-OH、Fmoc-Phe-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Lys(N-ε-(γ-Glu(N-α-Boc)-OtBu)-OH、
Fmoc-Ala-Ala-OH、Fmoc-Gln(Trt)-OH、Fmoc-Gly-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Leu-OH、
Fmoc-Tyr(tBu)-OH 、Fmoc-Ser(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Val-OH、Fmoc-Asp
(OtBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu) -OH 、Fmoc-Phe-OH、Fmoc-Thr(tBu) -OH 、
Fmoc-Gly-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Ala-OH、 Fmoc-His(Trt)--OH、(Tfa)2O obtains N-terminal
Full guard Liraglutide (unmodified) peptide resin of trifluoroacetylation: Tfa-His (Trt)-Ala-Glu (OtBu)-Gly-Thr
(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Val- Ser(tBu)-Ser(tBu)-Tyr(tBu)-Leu-Glu
(OtBu)-Gly-Gln(Trt)-Ala-Ala-Lys(N-ε-(γ-Glu(N-α-Boc)-OtBu)-Glu(OtBu)-Phe-Ile-
Ala-Trp(Boc)-Leu-Val-Arg(Pbf)-Gly-Arg(Pbf)- Gly-Wang resins;It is vacuum dried, weighing
Are as follows: 245.3g, resin weight gain 145.3g, rate of body weight gain 99.2%.
Embodiment 5: peptide resin cracking
Full guard Liraglutide (unmodified) peptide resin for the 240.0g N-terminal trifluoroacetylation that embodiment 4 is obtained, adds
Enter 2400ml lysate (the volume proportion TFA/TIS/H to freezing20=95/2.5/2.5) in, it is stirred to react 3h at room temperature;
Cracking reaction terminates, and filters resin, and 200mlTFA is washed resin 2 times, merging filtrate and washing lotion, concentrated by rotary evaporation to 1600ml,
Enter in the 16L freezing tertiary ether of first, white precipitate is precipitated;After standing 30min, filtering, the tertiary ether of first is washed 6 times, is dried in vacuo to obtain N-terminal three
The thick peptide 104.1g of fluoroacetylation Liraglutide (unmodified), thick peptide yield 94.9%, purity 76.8%.
Embodiment 6: the preparation of peptide resin
Accurately weighing 3 substitution degree of embodiment is 0.29mmol/g Fmoc-Gly-CTC Resins 51.7g (synthesis scale
It 15mmol) is placed in synthesis column, 500ml DCM is added and is swollen 30min;After leaching out DCM, 400ml DMF is washed 2 times, is added
20% piperidines/DMF solution 500ml is deprotected 2 times, reacts 10min and 10min respectively;Then with 400ml DMF, DCM, DMF points
It Xi Di not be 2 times;26.9g (45mmol) Fmoc-Arg (Pbf)-OH, 6.7g (49.5mmol) HOBT and 7.7ml is added
The DMF solution 300ml of (49.5mmol) DIC, drum N2It is stirred to react 2h, reaction end is subject to Kaiser reagent testing result,
After reaction reaches terminal, reaction solution is taken out, is washed respectively 2 times with 400ml DMF, DCM, DMF;Then it is deprotected again.Repeatedly
Circulate operation is coupled with protected amino acid one by one according to Liraglutide peptide sequence;Sequentially connected protected amino acid are as follows: Fmoc-
Gly-OH、Fmoc-Arg(Pbf)-OH、 Fmoc-Val-OH、Fmoc-Leu-OH、Fmoc-Trp(Boc)-OH、Fmoc-Ala-
OH、Fmoc-Ile-OH、Fmoc-Phe-OH、Fmoc-Glu(OtBu)-OH、Fmoc-Lys(N-ε-(γ-Glu(N-α-Boc)-
OtBu)-OH、Fmoc-Ala-Ala-OH、Fmoc-Gln(Trt)-OH、Fmoc-Gly-OH、Fmoc-Glu(OtBu)-OH、Fmoc-
Leu-OH、Fmoc-Tyr(tBu)-OH 、Fmoc-Ser(tBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Val-OH、Fmoc-
Asp(OtBu)-OH、Fmoc-Ser(tBu)-OH、Fmoc-Thr(tBu) -OH 、Fmoc-Phe-OH、Fmoc-Thr(tBu) -
OH, Fmoc-Gly-OH, Fmoc-Glu (OtBu)-OH, Fmoc-Ala-OH, Fmoc-His (Trt)-OH, (Tfa)2O obtains N
Hold full guard Liraglutide (unmodified) peptide resin of trifluoroacetylation: Tfa-His (Trt)-Ala-Glu (OtBu)-Gly-Thr
(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Val- Ser(tBu)-Ser(tBu)-Tyr(tBu)-Leu-Glu
(OtBu)-Gly-Gln(Trt)-Ala-Ala-Lys(N-ε-(γ-Glu(N-α-Boc)-OtBu)-Glu(OtBu)-Phe-Ile-
Ala-Trp(Boc)-Leu-Val-Arg(Pbf)-Gly-Arg(Pbf)- Gly-CTC resins;It is vacuum dried, weighing are as follows:
116.9g, resin weight gain 65.2g, rate of body weight gain 89.1%.
Embodiment 7: peptide resin cracking
Full guard Liraglutide (unmodified) peptide resin for the 115.0g N-terminal trifluoroacetylation that embodiment 6 is obtained, adds
Enter 1150ml lysate (the volume proportion TFA/TIS/H to freezing20=95/2.5/2.5) in, it is stirred to react 3h at room temperature;
Cracking reaction terminates, and filters resin, and 100mlTFA is washed resin 2 times, and merging filtrate and washing lotion, concentrated by rotary evaporation to 800ml are poured into
8L is freezed in the tertiary ether of first, and white precipitate is precipitated;After standing 30min, filtering, the tertiary ether of first is washed 6 times, is dried in vacuo to obtain N-terminal trifluoro
The thick peptide 47.6g of acetylation Liraglutide (unmodified), thick peptide yield 85.0%, purity 77.6%.
The purification of embodiment 8:N end trifluoroacetylation Liraglutide (unmodified)
The thick peptide 100.0g of 5 gained of embodiment is weighed to be dissolved in 10% acetonitrile solution 2500ml, after concussion dissolution, 0.45um
It is spare after membrane filtration.
Internal diameter is that 100mm C18 prepares column, and mobile phase is 0.1%TFA/ water -0.1%TFA/ acetonitrile system, and applied sample amount is
6.0g/ times, flow velocity 300ml/min, gradient elution;Recycle sample introduction behind before peak and peak, interception middle control analysis purity be 99.5% with
On, fine peptide 56.2g is lyophilized to obtain in single miscellaneous fine peptide solution less than 0.1% after concentration, purifying yield is 56.2%, and purity 99.6% is single
It is miscellaneous to be respectively less than 0.1%.
The purification of embodiment 9:N end trifluoroacetylation Liraglutide (unmodified)
The thick peptide 45.0g of 7 gained of embodiment is weighed to be dissolved in 10% acetonitrile solution 1200ml, after concussion dissolution, 0.45um filter
It is spare after film filtering.
Internal diameter is that 100mm C18 prepares column, and mobile phase is 0.1%TFA/ water -0.1%TFA/ acetonitrile system, and applied sample amount is
6.0g/ times, flow velocity 300ml/min, gradient elution;Recycle sample introduction behind before peak and peak, interception middle control analysis purity be 99.5% with
On, fine peptide 25.7g is lyophilized to obtain in single miscellaneous fine peptide solution less than 0.1% after concentration, purifying yield is 57.1%, and purity 99.6% is single
It is miscellaneous to be respectively less than 0.1%.
Embodiment 10: the preparation of Liraglutide
8 gained fine peptide 56.0g (15mmol) of embodiment is added in tri- mouthfuls of reaction flasks of 2L, 10% acetonitrile water of 1000ml is added
Under ice-water bath, 10% Na is slowly added dropwise in solution stirring and dissolving2CO3Aqueous solution adjusts pH value of solution to 11, stops being added dropwise;In ice water
Lower THF solution 7.1g (the 30mmol)/150ml that Pal-OSu is added dropwise of bath, is added dropwise, removes ice bath, react 3h at room temperature;It is added
2.25g (30mmol) glycine, the reaction was continued 30min, TLC monitor reaction end;
150ml piperidines is added under high degree of agitation into reaction solution, continues to stir at room temperature, HPLC monitors alkaline hydrolysis terminal;Instead
It should stop stirring, G3 sand core funnel filters out insoluble matter, and three times with pure water washing insoluble matter to after terminal;Merge washing lotion and
Filtrate is continuously added pure water dilution peptide solution, is kept liquor capacity constant with ultrafiltration apparatus desalination;When solution ph is down to 11
When, peptide solution is diluted using 0.5% aqueous acetic acid, until stopping filtering when pH value is down to 5.Filtrate through 0.45um membrane filtration,
For use.
Internal diameter is that 100mm C8 prepares column, and mobile phase is 20mM ammonium acetate aqueous solution-acetonitrile system, and applied sample amount is
3.0g/ times, flow velocity 300ml/min, gradient elution;Recycle sample introduction behind before peak and peak, interception middle control analysis purity be 99.5% with
On, single miscellaneous fine peptide solution less than 0.1% is concentrated freeze-dried that fine peptide 39.3g, yield 70.2%, purity 99.6% are single after desalination
It is miscellaneous to be respectively less than 0.1%;Preparing total recovery is 37.5%.
Embodiment 11: the preparation of Liraglutide
9 gained fine peptide 24.3g (6.5mmol) of embodiment is added in tri- mouthfuls of reaction flasks of 1L, 10% acetonitrile water of 500ml is added
Under ice-water bath, 10% EDPA/NMP solution is slowly added dropwise in solution stirring and dissolving, is adjusted pH value of solution to 11, is stopped being added dropwise;In ice water
Lower THF solution 4.6g (the 13mmol)/80ml that Pal-OSu is added dropwise of bath, is added dropwise, removes ice bath, react 3h at room temperature;It is added
0.98g (13mmol) glycine, the reaction was continued 30min, TLC monitor reaction end;
61ml piperidines is added under high degree of agitation into reaction solution, continues to stir at room temperature, HPLC monitors alkaline hydrolysis terminal;Reaction
To after terminal, stop stirring, G3 sand core funnel filters out insoluble matter, and three times with pure water washing insoluble matter;Merge washing lotion and filter
Liquid is continuously added pure water dilution peptide solution, is kept liquor capacity constant with ultrafiltration apparatus desalination;When solution ph is down to 11,
Peptide solution is diluted using 0.5% aqueous acetic acid, until stopping filtering when pH value is down to 5.Filtrate through 0.45um membrane filtration, to
With.
Internal diameter is that 100mm C8 prepares column, and mobile phase is 20mM ammonium acetate aqueous solution-acetonitrile system, and applied sample amount is
3.0g/ times, flow velocity 300ml/min, gradient elution;Recycle sample introduction behind before peak and peak, interception middle control analysis purity be 99.5% with
On, single miscellaneous fine peptide solution less than 0.1% is concentrated freeze-dried that fine peptide 17.3g, yield 71.1%, purity 99.6% are single after desalination
It is miscellaneous to be respectively less than 0.1%;Preparing total recovery is 34.5%.
Claims (7)
1. a kind of method that solid-liquid combination prepares Liraglutide, which comprises the steps of:
(a) Boc-Glu (OSu)-OtBu and Fmoc-Lys-OH is coupled under alkaline solution generates two peptide monomer Fmoc-Lys (N-
ε-(γ-Glu(N-α-Boc)-OtBu)-OH;Concrete operations are as follows: by Fmoc-Lys-OH or its salt and alkali A according to molar ratio 1:1
~2 ratio is dissolved in water, and the organic solvent B hydrotropy of 5~20% volumes is added, until completely dissolved, with Fmoc-Lys-OH
Meter, the organic solvent B solution of 1~1.2 times of mole Boc-Glu (OSu)-OtBu is added dropwise under stirring;It is anti-to continue stirring
It answers, TLC monitors reaction end, and after reaction, decompression evaporates organic solvent, and 10% aqueous citric acid solution tune solution ph is added
To 2~3, ethyl acetate extraction, crystallization obtains Fmoc-Lys (N- ε-(γ-Glu (N- α-Boc)-OtBu)-OH;
(b) using Wang resin or CTC resin as solid phase carrier, using Fmoc chemoproection strategy, according to Liraglutide peptide sequence, according to
The secondary full guard peptide resin that N-terminal trifluoroacetylation is synthesized with Fmoc protected amino acid, wherein 26 Lys of Fmoc protected amino acid are adopted
It is that (N- ε-(γ-Glu (N- α-Boc)-OtBu)-OH, 24 and 25 use Fmoc-Ala-Ala- to monomer Fmoc-Lys
OH, other sites are all made of conventional Fmoc protected amino acid coupling;The full guard peptide resin structure of N-terminal trifluoroacetylation is such as
Under:
Tfa-His(Trt)-Ala-Glu(OtBu)-Gly-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-
Val-Ser(tBu)-Ser(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Gly-Gln(Trt)-Ala-Ala-Lys(N-ε-
(γ-Glu(N-α-Boc)-OtBu)-Glu(OtBu)-Phe-Ile-Ala-Trp(Boc)-Leu-Val-Arg(Pbf)-Gly-
Arg (Pbf)-Gly- resin;
(c) the unmodified Liraglutide of trifluoroacetylation is obtained with lytic reagent peptide resin, and purified, obtains essence
Peptide:
Tfa-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-
Ala-Ala-Lys(γ-Glu-OH)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH;
(d) under alkaline condition, Pal-OSu and the unmodified Liraglutide fine peptide of step (c) gained trifluoroacetylation occur
Coupling reaction obtains the product of palmitinic acid modification;
(e) Liraglutide is obtained through alkaline hydrolysis, purifying, freeze-drying;
The alkali A be sodium carbonate, sodium bicarbonate, saleratus, potassium carbonate, triethylamine, diethylamine, N- ethyl diisopropyl amine,
One of N, N- diisopropylethylamine etc.;The organic solvent B be tetrahydrofuran, dioxane, N,N-dimethylformamide,
One of acetone, n-methyl-2-pyrrolidone, acetonitrile or more than one mixed liquor.
2. the method that solid-liquid combination according to claim 1 prepares Liraglutide, which is characterized in that N-terminal three in step (b)
The full guard peptide resin of fluoroacetylation specific is the preparation method comprises the following steps: using Wang resin or CTC resin as solid phase carrier, to synthesize rule
The substance meter of mould is added corresponding Fmoc protected amino acid with 2-5 times of feed ratio and carries out coupling reaction, each coupling is anti-
Should be the solid phase peptide reaction carried out in the presence of condensing agent, after completion of the reaction with deprotecting regent remove Fmoc, then with
Next Fmoc protected amino acid carries out coupling reaction;After repetitive operation is until be blended into 1 His, blocked with trifluoroacetic anhydride,
Obtain full guard peptide resin Tfa-His (Trt)-Ala-Glu (OtBu)-Gly-Thr (tBu)-Phe- of N-terminal trifluoroacetylation
Thr(tBu)-Ser(tBu)-Asp(OtBu)-Val-Ser(tBu)-Ser(tBu)-Tyr(tBu)-Leu-Glu(OtBu)-Gly-
Gln(Trt)-Ala-Ala-Lys(N-ε-(γ-Glu(N-α-Boc)-OtBu)-Glu(OtBu)-Phe-Ile-Ala-Trp
(Boc)-Leu-Val-Arg (Pbf)-Gly-Arg (Pbf)-Gly- resin.
3. the method that solid-liquid combination according to claim 2 prepares Liraglutide, which is characterized in that Wang resin or CTC
The substitution degree of resin is 0.3-0.5mmol/g.
4. the method that solid-liquid combination according to claim 2 prepares Liraglutide, which is characterized in that condensing agent DIC/
One kind of HOBT, DIC/HOAT, TBTU/HOBT/DIPEA, HBTU/HOBT/DIPEA, HATU/HOAT/DIPEA;Deprotection examination
Agent is piperidines/DMF solution of volume content 15~25%.
5. the method that solid-liquid combination prepares Liraglutide according to claim 1, which is characterized in that split described in step (c)
Solution reagent be added volume ratio 1-5% scavenger TFA solution, the scavenger be methyl phenyl ethers anisole, thioanisole, dithioglycol,
One or more of mercaptoethanol, phenol, water, tri isopropyl silane.
6. the method that solid-liquid combination according to claim 1 prepares Liraglutide, which is characterized in that step (d) it is specific
Operating procedure are as follows: take fine peptide obtained by step (c) and alkali A to be dissolved in water according to the ratio of molar ratio 1:4~6, volume ratio 5 is added
~20% organic solvent B hydrotropy with the meter of fine peptide, is added dropwise to 1~2.0 times of mole until completely dissolved under stirring
The organic solvent B solution of Pal-OSu;Continue to be stirred to react, TLC monitors reaction end;After reaction reaches terminal, with the amount of fine peptide
The glycine of 1~2.0 times of mole is added in meter, terminates reaction.
7. the method that solid-liquid combination according to claim 1 prepares Liraglutide, which is characterized in that alkaline hydrolysis in step (e)
Concrete operation step are as follows: in terms of the resulting liquor capacity of step (d), measure volume ratio 10-12% piperidines, be added step
(d) it is configured to the piperidine solution that concentration is 1M in resulting solution, is stirred to react complete to trifluoroacetyl group alkaline hydrolysis;Then through super
Device desalination is filtered, pure water dilution peptide solution is continuously added, keeps liquor capacity constant;When solution ph is down to 12~10, adopt
Peptide solution is diluted with 0.2-1.0% aqueous acetic acid, until stopping filtering when pH value is down to 5~6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510347921.XA CN105111303B (en) | 2015-06-23 | 2015-06-23 | A kind of method that solid-liquid combination prepares Liraglutide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510347921.XA CN105111303B (en) | 2015-06-23 | 2015-06-23 | A kind of method that solid-liquid combination prepares Liraglutide |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105111303A CN105111303A (en) | 2015-12-02 |
CN105111303B true CN105111303B (en) | 2019-07-26 |
Family
ID=54659448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510347921.XA Expired - Fee Related CN105111303B (en) | 2015-06-23 | 2015-06-23 | A kind of method that solid-liquid combination prepares Liraglutide |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105111303B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2624961T3 (en) | 2013-03-21 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Synthesis of peptide products containing cyclic imide |
US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
CN106928313B (en) * | 2015-12-31 | 2020-12-11 | 深圳翰宇药业股份有限公司 | Synthesis method of C-terminal modified peptide |
CN107446025B (en) * | 2017-09-20 | 2020-03-31 | 上海丽珠制药有限公司 | Preparation method of alarelin |
EP3666789A1 (en) * | 2018-12-14 | 2020-06-17 | Wntresearch AB | Linear solution phase routes for wnt hexapeptides |
JP2022526115A (en) * | 2019-03-19 | 2022-05-23 | エンゼン・バイオサイエンシズ・リミテッド | Glucagon-like peptide-1 (GLP-1) receptor agonist and its analog manufacturing process |
CN110028573A (en) * | 2019-05-14 | 2019-07-19 | 山东汉泰生物科技有限公司 | A kind of method that solid-liquid combination prepares Liraglutide |
CN113984911A (en) * | 2020-07-27 | 2022-01-28 | 宁波鲲鹏生物科技有限公司 | Chromatographic method for simultaneously analyzing liraglutide and Boc-liraglutide main chain thereof |
CN111732649B (en) * | 2020-08-04 | 2020-12-08 | 苏州金顶生物有限公司 | Preparation of liraglutide by continuous flow solid phase reaction |
EP4345104B1 (en) | 2022-09-30 | 2024-08-28 | Bachem Holding AG | Method for preparing liraglutide |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4758623A (en) * | 1986-07-17 | 1988-07-19 | Schering Corporation | Trifluoroacetylation of unhindered primary and secondary amines and polymer-bound trifluoroacetylation reagents |
CN103275209A (en) * | 2013-05-27 | 2013-09-04 | 成都圣诺生物制药有限公司 | Liraglutide preparation method |
CN103304660A (en) * | 2013-07-12 | 2013-09-18 | 上海昂博生物技术有限公司 | Synthetic method of liraglutide |
CN104356221A (en) * | 2014-10-24 | 2015-02-18 | 杭州阿德莱诺泰制药技术有限公司 | Preparation method of pexiganan |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104045706B (en) * | 2013-03-12 | 2017-09-05 | 深圳翰宇药业股份有限公司 | A kind of synthetic method of Liraglutide |
-
2015
- 2015-06-23 CN CN201510347921.XA patent/CN105111303B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4758623A (en) * | 1986-07-17 | 1988-07-19 | Schering Corporation | Trifluoroacetylation of unhindered primary and secondary amines and polymer-bound trifluoroacetylation reagents |
CN103275209A (en) * | 2013-05-27 | 2013-09-04 | 成都圣诺生物制药有限公司 | Liraglutide preparation method |
CN103304660A (en) * | 2013-07-12 | 2013-09-18 | 上海昂博生物技术有限公司 | Synthetic method of liraglutide |
CN104356221A (en) * | 2014-10-24 | 2015-02-18 | 杭州阿德莱诺泰制药技术有限公司 | Preparation method of pexiganan |
Non-Patent Citations (1)
Title |
---|
《有机合成中的氨基保护及应用(综述)》;高旭红 等;《石河子大学学报(自然科学版)》;19990228;第3卷(第1期);第78页倒数第一段 |
Also Published As
Publication number | Publication date |
---|---|
CN105111303A (en) | 2015-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105111303B (en) | A kind of method that solid-liquid combination prepares Liraglutide | |
US11518794B2 (en) | Synthesis method for liraglutide with low racemate impurity | |
CN108059666B (en) | A kind of method that solid-liquid combination prepares Suo Malu peptides | |
CN109180801B (en) | Method for synthesizing Somalutide | |
CN105732798B (en) | A kind of synthetic method of Liraglutide | |
CN111732651B (en) | Method for preparing Somalutide through continuous flow solid phase reaction | |
CN102875655B (en) | Linaclotide synthesis method | |
CN104987382B (en) | A kind of method that dipeptide fragment Liquid solid Bonding prepares thymalfasin | |
CN105384809B (en) | A kind of method that segment method solid-liquid combination prepares Teriparatide | |
CN104031127B (en) | A kind of solid-liquid combination prepares the method for bivalirudin | |
CN106749613A (en) | A kind of synthetic method of Suo Malu peptides | |
CN111732650B (en) | Continuous flow solid phase reaction preparation of Somaloutide | |
CN110028573A (en) | A kind of method that solid-liquid combination prepares Liraglutide | |
CN113135991B (en) | Method for preparing somaglutide | |
CN110372785A (en) | A kind of synthetic method of Suo Malu peptide | |
CN111732649B (en) | Preparation of liraglutide by continuous flow solid phase reaction | |
CN105418736A (en) | Preparation method of terlipressin through combination of solid and liquid | |
CN109734794A (en) | A kind of preparation method of A Bapa peptide | |
CN106478805A (en) | A kind of preparation method of GLP-1 derivant | |
CN106749614A (en) | A kind of fragment method solid-liquid combination is prepared for the method for degree Shandong peptide | |
CN113880936A (en) | Solid-phase synthesis method of abamectin | |
CN115991742A (en) | Solid phase synthesis method of telipopeptide | |
CN105348367A (en) | Method for preparing carbetocin through solid phase and liquid combining method | |
CN106243214A (en) | A kind of preparation method of melanotan I | |
CN115677827A (en) | Peptide compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190726 |